Cargando…
Anti-Viral Therapy and Decreased Sexual Desire in Patients with Chronic Hepatitis C
PURPOSE: Peg-interferon (PegIFN)α2a or PegIFNα2b plus ribavirin (RBV) is the standard therapy for chronic hepatitis C virus (HCV) infection in Taiwan and Asia. It is commonly associated with adverse effects, but the issue of sexual and mental health is not well reported. This study aimed to evaluate...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4978384/ https://www.ncbi.nlm.nih.gov/pubmed/27505293 http://dx.doi.org/10.1371/journal.pone.0160450 |
_version_ | 1782447162422984704 |
---|---|
author | Hsiao, Po-Jen Hsieh, Po-Fan Chou, Eric Chieh-Lung Lai, Hsueh–Chou Peng, Cheng-Yuan Su, Kuan-Pin |
author_facet | Hsiao, Po-Jen Hsieh, Po-Fan Chou, Eric Chieh-Lung Lai, Hsueh–Chou Peng, Cheng-Yuan Su, Kuan-Pin |
author_sort | Hsiao, Po-Jen |
collection | PubMed |
description | PURPOSE: Peg-interferon (PegIFN)α2a or PegIFNα2b plus ribavirin (RBV) is the standard therapy for chronic hepatitis C virus (HCV) infection in Taiwan and Asia. It is commonly associated with adverse effects, but the issue of sexual and mental health is not well reported. This study aimed to evaluate the impact of anti-viral therapy with PegIFNα plus RBV on sexual desire and depression. METHODS: This prospective cohort study from 2009 to 2014 enrolled 181 patients with HCV who received PegIFNα2a (180 mcg/week) or PegIFNα2b (1.5 mcg/Kg/week) plus RBV (800–1200 mg/day) according to response-guide therapy for 24 to 48 weeks in a tertiary medical center. Patients with decreased sexual desire (DSD) before PegIFNα plus RBV were excluded. Patients were evaluated at baseline (week 0) and after 2, 4, 8, 12, 16, 20, and 24 weeks of PegIFNα plus RBV treatment using the structured Mini-International Neuropsychiatric Interview, for the diagnosis of a major depressive episode, and the 21-item Beck Depression Inventory (BDI), for monitoring depressive symptoms. The 21st item of the BDI was used to evaluate DSD. RESULTS: During therapy, 124 (68.5%) patients had DSD. The BDI score peaked at 14.8 weeks. The severity of DSD was greatest at 16 weeks of treatment. The average score of the 21st item of the BDI correlated with DSD. Depression history and the prevalence of subsequent major depressive disorder after anti-viral therapy was correlated to DSD (p = 0.05 and 0.001). Male patients complained of DSD more significantly than females (p = 0.031). CONCLUSIONS: Decreased sexual desire is common but is usually neglected in patients with chronic hepatitis C undergoing anti-viral therapy, especially among male patients. Physicians must be monitoring the side effects of sexual health and depression. |
format | Online Article Text |
id | pubmed-4978384 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-49783842016-08-25 Anti-Viral Therapy and Decreased Sexual Desire in Patients with Chronic Hepatitis C Hsiao, Po-Jen Hsieh, Po-Fan Chou, Eric Chieh-Lung Lai, Hsueh–Chou Peng, Cheng-Yuan Su, Kuan-Pin PLoS One Research Article PURPOSE: Peg-interferon (PegIFN)α2a or PegIFNα2b plus ribavirin (RBV) is the standard therapy for chronic hepatitis C virus (HCV) infection in Taiwan and Asia. It is commonly associated with adverse effects, but the issue of sexual and mental health is not well reported. This study aimed to evaluate the impact of anti-viral therapy with PegIFNα plus RBV on sexual desire and depression. METHODS: This prospective cohort study from 2009 to 2014 enrolled 181 patients with HCV who received PegIFNα2a (180 mcg/week) or PegIFNα2b (1.5 mcg/Kg/week) plus RBV (800–1200 mg/day) according to response-guide therapy for 24 to 48 weeks in a tertiary medical center. Patients with decreased sexual desire (DSD) before PegIFNα plus RBV were excluded. Patients were evaluated at baseline (week 0) and after 2, 4, 8, 12, 16, 20, and 24 weeks of PegIFNα plus RBV treatment using the structured Mini-International Neuropsychiatric Interview, for the diagnosis of a major depressive episode, and the 21-item Beck Depression Inventory (BDI), for monitoring depressive symptoms. The 21st item of the BDI was used to evaluate DSD. RESULTS: During therapy, 124 (68.5%) patients had DSD. The BDI score peaked at 14.8 weeks. The severity of DSD was greatest at 16 weeks of treatment. The average score of the 21st item of the BDI correlated with DSD. Depression history and the prevalence of subsequent major depressive disorder after anti-viral therapy was correlated to DSD (p = 0.05 and 0.001). Male patients complained of DSD more significantly than females (p = 0.031). CONCLUSIONS: Decreased sexual desire is common but is usually neglected in patients with chronic hepatitis C undergoing anti-viral therapy, especially among male patients. Physicians must be monitoring the side effects of sexual health and depression. Public Library of Science 2016-08-09 /pmc/articles/PMC4978384/ /pubmed/27505293 http://dx.doi.org/10.1371/journal.pone.0160450 Text en © 2016 Hsiao et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Hsiao, Po-Jen Hsieh, Po-Fan Chou, Eric Chieh-Lung Lai, Hsueh–Chou Peng, Cheng-Yuan Su, Kuan-Pin Anti-Viral Therapy and Decreased Sexual Desire in Patients with Chronic Hepatitis C |
title | Anti-Viral Therapy and Decreased Sexual Desire in Patients with Chronic Hepatitis C |
title_full | Anti-Viral Therapy and Decreased Sexual Desire in Patients with Chronic Hepatitis C |
title_fullStr | Anti-Viral Therapy and Decreased Sexual Desire in Patients with Chronic Hepatitis C |
title_full_unstemmed | Anti-Viral Therapy and Decreased Sexual Desire in Patients with Chronic Hepatitis C |
title_short | Anti-Viral Therapy and Decreased Sexual Desire in Patients with Chronic Hepatitis C |
title_sort | anti-viral therapy and decreased sexual desire in patients with chronic hepatitis c |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4978384/ https://www.ncbi.nlm.nih.gov/pubmed/27505293 http://dx.doi.org/10.1371/journal.pone.0160450 |
work_keys_str_mv | AT hsiaopojen antiviraltherapyanddecreasedsexualdesireinpatientswithchronichepatitisc AT hsiehpofan antiviraltherapyanddecreasedsexualdesireinpatientswithchronichepatitisc AT chouericchiehlung antiviraltherapyanddecreasedsexualdesireinpatientswithchronichepatitisc AT laihsuehchou antiviraltherapyanddecreasedsexualdesireinpatientswithchronichepatitisc AT pengchengyuan antiviraltherapyanddecreasedsexualdesireinpatientswithchronichepatitisc AT sukuanpin antiviraltherapyanddecreasedsexualdesireinpatientswithchronichepatitisc |